Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

The user is frustrated with hair loss treatments like finasteride, minoxidil, dutasteride, and oral minoxidil, which have been ineffective and caused scalp itching. They are skeptical about these treatments' effectiveness and consider alternative options like ketoconazole shampoo and RU58841.

The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.

Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.

The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.

Theaflavin, a black tea extract, may inhibit DHT and androgen receptor activity, but its effectiveness for hair loss is debated. Users report no significant improvement with theaflavin, while some find beta sitosterol helpful.

Minoxidil with alcohol and propylene glycol was more effective than non-alcohol versions, and RU58841 worked best in a non-water-based solution. Oral finasteride showed better results than topical, despite side effects; microneedling and tretinoin worsened hair loss, and PRP was only helpful when younger.

Concerns about the effectiveness of DHT inhibitors like finasteride and minoxidil due to potential polymorph issues. Experts suggest these concerns are largely unfounded, especially compared to rare cases like ritonavir.

The user is using dutasteride, finasteride, and RU58841 for hair loss but is allergic to minoxidil. Suggestions include dropping finasteride, increasing dutasteride dosage, and considering alternatives like microneedling, laser treatments, scalp massage, and supplements.

The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

Plant-based exosomes for hair loss lack scientific evidence and are considered high-risk with low evidence. Combining PRF with minoxidil and finasteride is suggested as a better option.

Hair loss treatments discussed include Minoxidil, Finasteride, RU58841, ass hair transplant, topical Viagra, castration, and transitioning to female. A user mentions an experimental drug called M4U-5 (Mousteride) that turns you into a mouse.

The conversation discusses using aromatase inhibitors with dutasteride or finasteride for hair loss, which can prevent testosterone from turning into estrogen but may lead to increased DHT and potentially make finasteride less effective. There's concern about proper dosing and side effects like gynecomastia and emotional changes.

The conversation humorously discusses hair loss treatments, including Minoxidil, finasteride, RU58841, and topical 17 alpha estradiol, with some users joking about transitioning to female to avoid baldness. The overall tone is satirical, emphasizing self-acceptance and the lengths people might consider for hair restoration.

Minoxidil may suppress androgen activity in hair follicles, potentially aiding in hair growth and prostate cancer treatment. Users discuss the effectiveness of minoxidil and finasteride for hair maintenance and regrowth, with some preferring topical applications over oral due to safety concerns.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

The conversation discusses hair loss treatments, specifically seeking a trusted supplier for RU58841. Minoxidil and finasteride are also mentioned as treatments.

The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

A satirical take on the effects of using Verteporfin as a treatment for hair loss, with people pointing out that it is not accurate and has exaggerated outcomes. It was suggested that instead Minoxidil, Finasteride, or RU58841 should be used to treat hair loss.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The conversation discusses skepticism towards unconventional hair loss remedies, emphasizing the effectiveness of proven treatments like oral DHT blockers, topical minoxidil, and finasteride. It criticizes misleading advice and highlights the importance of starting effective treatments early.

The conversation is about managing hair loss while on hormone replacement therapy (HRT) with estrogen and spironolactone. The user considers adding finasteride but decides to wait and see the effects of the current treatment.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.